The impact of industry group culture on the development of opportunism in cross-sector alliances

Over the last two decades the world economy has dramatically transformed, with strategic alliances and partnerships across industrial and global boundaries becoming an important means to maintaining and regaining competitive positioning. In spite of an increase in partnership activity, alliances continue to face problems fuelled by factors such as partner opportunism, and cultural incompatibility. This paper highlights the emergence of opportunism in alliances arising from cross-sectoral partners’ differences in cultural values and norms. The literature indicates that cultural differences are important factors for understanding the behaviour of managers across sectors

Investigating the role of uncoupling of troponin I phosphorylation from changes in myofibrillar Ca(2+)-sensitivity in the pathogenesis of cardiomyopathy.

Contraction in the mammalian heart is controlled by the intracellular Ca2+ concentration as it is in all striated muscle, but the heart has an additional signalling system that comes into play to increase heart rate and cardiac output during exercise or stress. β-adrenergic stimulation of heart muscle cells leads to release of cyclic-AMP and the activation of protein kinase A which phosphorylates key proteins in the sarcolemma, sarcoplasmic reticulum and contractile apparatus. Troponin I (TnI) and Myosin Binding Protein C (MyBP-C) are the prime targets in the myofilaments. TnI phosphorylation lowers myofibrillar Ca2+-sensitivity and increases the speed of Ca2+-dissociation and relaxation (lusitropic effect).Recent studies have shown that this relationship between Ca2+-sensitivity and TnI phosphorylation may be unstable. In familial cardiomyopathies, both dilated and hypertrophic (DCM and HCM), a mutation in one of the proteins of the thin filament often results in the loss of the relationship (uncoupling) and blunting of the lusitropic response. For familial dilated cardiomyopathy in thin filament proteins it has been proposed that this uncoupling is causative of the phenotype. Uncoupling has also been found in human heart tissue from patients with hypertrophic obstructive cardiomyopathy as a secondary effect. Recently, it has been found that Ca2+-sensitizing drugs can promote uncoupling, whilst one Ca2+-desensitising drug Epigallocatechin 3-Gallate (EGCG) can reverse uncoupling.We will discuss recent findings about the role of uncoupling in the development of cardiomyopathies and the molecular mechanism of the process

A pressão coronária (às vezes) mente. . .

Comment on: Comparative analysis of fractional flow reserve and instantaneous wave-free ratio: Results of a five-year registry. [Rev Port Cardiol. 2018]info:eu-repo/semantics/publishedVersio

Probing the secrets of Alzheimer's disease using human-induced pluripotent stem cell technology.

Our understanding of Alzheimer's disease (AD) is still incomplete and, as a result, we lack effective therapies. Reprogramming to generate human-induced pluripotent stem cells provides a new approach to the generation of human neurons that carry the genomes of people with familial or sporadic AD. Differentiation of such stem cells to human neurons is already providing new insights into AD and molecular pathways that may provide new targets for effective therapy. These pathways include typical amyloid response pathways, as well as pathways leading from altered behavior of amyloid precursor protein to the elevated phosphorylation of tau protein. There is also a need for standardization of models so that isogenic lines differing only in the familial AD mutation can be compared

CHANGES IN RUNNING GAIT PARAMETERS DURING A 161 KM TRAIL RACE

The current study examined changes in running speed and technique during a 161 km trail race and their relationship to performance. Sixteen participants were video recorded during continuous running for each of the five 32 km loops of the race. Participant's stride length (SL), stride rate (SR), and speed were calculated. Lap and finish times were also collated from the race results. All variables changed significantly during the race (i.e. Speed↓, Lap time↑, SL↓ and SR↓). Increased consistency in stride rate and length across the five laps, as well as speed, correlated positively with performance. Increased stride length in laps one, two and four correlated positively with performance. Results indicated that fatigue during the race decreased both speed and SL. Better performers ran faster with a longer SL and were able to maintain their initial speed for longer

MiRNAs as novel adipokines : obesity-related circulating MiRNAs influence chemosensitivity in cancer patients

Adipose tissue is an endocrine organ, capable of regulating distant physiological processes in other tissues via the release of adipokines into the bloodstream. Recently, circulating adipose-derived microRNAs (miRNAs) have been proposed as a novel class of adipokine, due to their capacity to regulate gene expression in tissues other than fat. Circulating levels of adipokines are known to be altered in obese individuals compared with typical weight individuals and are linked to poorer health outcomes. For example, obese individuals are known to be more prone to the development of some cancers, and less likely to achieve event-free survival following chemotherapy. The purpose of this review was twofold; first to identify circulating miRNAs which are reproducibly altered in obesity, and secondly to identify mechanisms by which these obesity-linked miRNAs might influence the sensitivity of tumors to treatment. We identified 8 candidate circulating miRNAs with altered levels in obese individuals (6 increased, 2 decreased). A second literature review was then performed to investigate if these candidates might have a role in mediating resistance to cancer treatment. All of the circulating miRNAs identified were capable of mediating responses to cancer treatment at the cellular level, and so this review provides novel insights which can be used by future studies which aim to improve obese patient outcomes